Leading Developer of Transformative Hip Arthroplasty Solutions

The Polymotion® Hip Resurfacing (PHR®) IDE study has officially passed the 60% enrolment mark, bringing us another step closer to completing this pivotal trial. This achievement underscores the accelerating pace of patient recruitment and the strong interest in next-generation hip resurfacing within the U.S.

A recent study published in International Orthopaedics (2025) reports the longest follow-up to date on the outcomes of hip resurfacing arthroplasty (HRA) in patients under the age of 30. Conducted by Girard et al. at the University of Lille, the research addresses a critical gap in orthopaedic literature, as few long-term data have been available for such a young and active patient population. The retrospective study reviewed the clinical data, and patient recorded outcome measures (PROM’s) of 103 HRAs performed in 93 patients (77 men, 16 women) with a mean age of 27.7 years. Key Outcomes: -The study reported a 98% survivorship rate free from revision at 10.8 years. -Report demonstrated low complication rates with no dislocations or adverse wear related failures reported Patients demonstrated statistically significant improvements in hip function and activity levels following hip resurfacing arthroplasty (HRA) i.e. Harris Hip Score (HHS): improved from 41.9 preoperatively to 92.8 postoperatively JM Comments: The findings of this study highlight the versatility of HRA and its value in addressing the needs of an increasingly diverse patient population. Importantly, the study concludes that HRA is a safe and effective alternative to total hip arthroplasty (THA) in young, active patients, enabling a return to sport and high-impact activities. Reference: Girard J, Putman S, Migaud H, Urbain A, Faure PA. Ten year follow-up of hip resurfacing in patients under thirty years old. Int Orthop. 2025 Aug;49(8):1853-1860. doi: 10.1007/s00264-025-06558-5. Epub 2025 May 16. PMID: 40377662.

JointMedica, a global leader in orthopedic innovation, announces the commencement of an Investigational Device Exemption (IDE) study for its Polymotion® Hip Resurfacing (PHR®) device.

We are pleased to announce that the Polymotion® Hip Resurfacing (PHR®) IDE study has now reached 30% of its target enrolment.

In a recent network meta-analysis “Hip resurfacing arthroplasty reduces dislocation and infection rates without differences in clinical outcomes compared to short and standard stems

In a systematic review published earlier this year, Marwin et al. (2025) stated “There is no significant difference in postoperative outcomes between younger and older patients undergoing HRA.